When was A-Alpha Bio founded?

A-Alpha Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is A-Alpha Bio located?

A-Alpha Bio is headquartered in Seattle, United States.

How many employees does A-Alpha Bio have?

As of Jun 30, 2026, the latest employee count at A-Alpha Bio is 49.

Is A-Alpha Bio a funded company?

A-Alpha Bio is a funded company, having raised a total of $45.2M across 10 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 01, 2018.

When was the latest funding round of A-Alpha Bio?

A-Alpha Bio's latest funding was a $***** Grant (prize money) round on May 21, 2024, with participation from 1 investor.

Where does A-Alpha Bio rank among its competitors?

A-Alpha Bio ranks 5th amongst 174 active competitors, of which 30 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Arzeda, which secured $4.51M in Aug, 2025.

Who are the top competitors of A-Alpha Bio?

A-Alpha Bio's top competitors include Nautilus Biotechnology, Somalogic and Biognosys. Among them, Arzeda secured the most recent funding round in August, 2025.

A-Alpha Bio - 2026 Company Profile, Team, Funding & Competitors

A-Alpha Bio is a series A company based in Seattle (United States), founded in 2017 by Randolph Lopez and David Younger. It operates as a Developer of cell-based tool for the measurements of protein interactions. A-Alpha Bio has raised $45.2M in funding from investors like Madrona, OS Fund and Xontogeny. The company has 174 active competitors, including 30 funded and 27 that have exited. Its top competitors include companies like Nautilus Biotechnology, Somalogic and Biognosys.

Company Details

Developer of cell-based tool for the measurements of protein interactions. The company offers cell-based platform technology that measures protein interactions with the help of engineered yeast cells. It enhances drug development by measuring protein interactions.

Website: www.aalphabio.com/
Social
Email ID: *****@aalphabio.com

Key Metrics

Founded Year

2017

Location

Seattle, United States

Stage

Series A

Total Funding

$45.2M in 10 rounds

Latest Funding Round

Grant (prize money), May 21, 2024, $*****

Investors

Madrona & 16 more

Ranked

5^th among 174 active competitors

Employee Count

49 as on Jun 30, 2026

Similar Companies

Nautilus Biotechnology & 234 more

View A-Alpha Bio's full profile

A-Alpha Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
A-alpha Bio, Inc. CIN: 823070666 , United States, Active	Dec 31, 1999	-	48 (As on Dec 31, 2024)	-

A-Alpha Bio has raised a total funding of $45.2M over 10 rounds. Its first funding round was on Jul 01, 2018. Its latest funding round was a Grant (prize money) round on May 21, 2024 for $*****. 1 investor participated in its latest round. A-Alpha Bio has 17 institutional investors.

Here is the list of recent funding rounds of A-Alpha Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 21, 2024	4888446	Grant (prize money)	7528607	3962281	3685086	6604007
Jul 25, 2023	4655309	Series A	3408920	3909882	4163814	Breakout Ventures & 1 more
May 2023	6170696	Grant (prize money)	7517177	5436117	8147173	Defense.gov

Access funding benchmarks and valuations. Sign up today!

View details of A-Alpha Bio's funding rounds and investors

The founders of A-Alpha Bio are Randolph Lopez and David Younger.

Here are the details of A-Alpha Bio's key team members:

Randolph Lopez: Co-founder & CTO of A-Alpha Bio.
Contact Info: 1 email address
David Younger: Founder & CEO of A-Alpha Bio.
Contact Info: 1 email address

A-Alpha Bio's Board of Directors

A-Alpha Bio's board has 4 active members. Matt Mcilwain, David Younger, Randolph Lopez Barrezueta and Ben Askew are independent board members.

Here is the list of A-Alpha Bio's board of directors:

Name	Type	Representing	Status	Duration
Matt Mcilwain	Independent board member	-	Current	4y 10m
euprnum	Independent board member	-	Current	6y 1m
dtkehqf	Independent board member	-	Current	7y 4m
uwzgpcd	Independent board member	-	Current	2y 7m

View details of A-Alpha Bio's Founder profiles and Board Members

A-Alpha Bio's employee count trend

A-Alpha Bio has 49 employees as of Jun 26. Here is A-Alpha Bio's employee count trend over the years:

Uncover A-Alpha Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of A-Alpha Bio include Nautilus Biotechnology, Somalogic and Biognosys. Here is the list of Top 10 competitors of A-Alpha Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nautilus Biotechnology 2016, Seattle (United States), Public	Developer of proteomics platform for drug development	$453M	Vulcan, Bain Capital Life Sciences & 8 others	65/100
2nd	Somalogic 1999, Boulder (United States), Acquired	Developer of protein-based assays for life science research	$664M	ProQuest Investments, ICarbonX & 27 others	64/100
3rd	Biognosys 2008, Schlieren (Switzerland), Acquired	Provider of proteomics service	$9.13M	Syngenta Group, Zurcher Kantonalbank & 6 others	63/100
4th	Arzeda 2008, Seattle (United States), Series B	Developer of enzyme design technology to bridge the gap by creating synthetic enzymes	$95.2M	OS Fund, Conti Ventures & 22 others	59/100
5th	A-Alpha Bio 2017, Seattle (United States), Series A	Developer of cell-based tool for the measurements of protein interactions	$45.2M	AME Cloud Ventures, Xontogeny & 15 others	57/100
6th	Mursla 2017, London (United Kingdom), Seed	Provider of diagnostic device for cancer detection	$547K	Future Fund, TA Ventures & 26 others	55/100
7th	ProteinSimple 2004, San Jose (United States), Acquired	Provider tools to help researchers with protein analysis	$94.3M	Lansing Brown Investments, Royal Bank of Canada ... & 10 others	54/100
8th	Amunix 2006, Mountain View (United States), Acquired	Developer of peptide-based therapeutics	$201M	Omega Funds, Viking Global Investors & 18 others	49/100
9th	Dynamic Biosensors 2011, Planegg (Germany), Acquired	Provides solutions for label-free molecular interaction and biophysical analysis	$5.83M	Rurode, BioM & 19 others	49/100
10th	Akonni 2003, Frederick (United States), Series C	Molecular diagnostics and sample prep solutions for high-quality nucleic acid purification	$39.7M	Righton, National Science Foundation & 5 others	49/100